Alpha-1 Antitrypsin Deficiency Disease Treatment Market Size & Share 2026-2035

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Size

The global alpha-1 antitrypsin deficiency disease treatment market was valued at USD 3.1 billion in 2025. The market is expected to grow from USD 3.3 billion in 2026 to USD 6.8 billion in 2035, at a CAGR of 8.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

Market growth is primarily driven by the increasing prevalence of alpha-1 antitrypsin deficiency (AATD)-associated respiratory and liver disorders, rising awareness regarding rare genetic diseases, expanding screening initiatives, and continuous advancements in diagnostic and therapeutic technologies. The growing burden of chronic obstructive pulmonary disease (COPD), emphysema, liver cirrhosis, and related pulmonary complications linked to AATD is further accelerating demand for effective treatment solutions. For instance, according to the American Lung Association, approximately 80,000 to 100,000 individuals in the U.S. are living with alpha-1 antitrypsin deficiency, significantly increasing their susceptibility to COPD and other chronic lung diseases. This rising patient population highlights the increasing need for advanced therapies and early intervention strategies. In addition, technological advancements in genetic and molecular diagnostics are enabling earlier detection of AATD, supporting timely diagnosis, personalized treatment planning, and improved disease management outcomes, thereby contributing to market expansion.

Alpha-1 antitrypsin (AAT) is a protein produced in the liver that plays a critical role in protecting the lungs from inflammatory damage. Deficiency of this protein can lead to severe pulmonary and hepatic complications, particularly when combined with environmental risk factors such as smoking, dust exposure, and air pollution. The market comprises diagnostic solutions, augmentation therapies, gene-based therapies, inhalation therapies, and supportive treatment approaches aimed at managing AATD-associated conditions. Key treatment modalities include plasma-derived augmentation therapy, recombinant therapies, RNA-based therapeutics, gene-editing technologies, liver transplantation in advanced cases, and lifestyle modification strategies.

Key companies operating in the alpha-1 antitrypsin deficiency disease treatment market include CSL Behring, Grifols, Takeda Pharmaceutical Company, Kamada, Baxter International, AstraZeneca, GlaxoSmithKline, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and Intellia Therapeutics. These companies are focusing on strengthening their rare disease portfolios through the development of advanced augmentation therapies, RNA interference technologies, gene-editing platforms, and next-generation biologics. Strategic collaborations, clinical trial expansions, and investments in biologics manufacturing capabilities are also supporting innovation and improving treatment accessibility across global markets.

Between 2022 and 2024, the market witnessed steady expansion, supported by increasing disease awareness, improved diagnostic rates, and rising adoption of augmentation therapies for AATD-related pulmonary disorders. During this period, the market grew from approximately USD 2.5 billion in 2022 to nearly USD 2.9 billion in 2024. Growth was further supported by ongoing investments in research and development related to RNA interference therapeutics, gene therapy, and novel biologic treatment approaches, along with broader availability of rare disease therapies across North America, Europe, and selected emerging economies.
 

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Trends

• The growth of the alpha-1 antitrypsin deficiency (AATD) disease treatment market is primarily driven by the rising prevalence of alpha-1 antitrypsin deficiency worldwide.
• AATD is a hereditary disorder associated with severe respiratory and liver conditions, including chronic obstructive pulmonary disease (COPD), emphysema, and liver cirrhosis, and is estimated to affect nearly 1 in 2,500 individuals globally.
• Although the disease remains significantly underdiagnosed, increasing awareness among healthcare professionals and the general population, coupled with improvements in diagnostic technologies, is leading to higher diagnosis rates and earlier disease detection. This is subsequently increasing demand for effective therapeutic interventions.
• The growing patient pool is creating substantial demand for augmentation therapies, gene therapies, inhalation therapies, and other advanced treatment approaches aimed at slowing disease progression and improving patient outcomes.
• Pharmaceutical and biotechnology companies are increasingly investing in the development of novel therapeutics and disease-modifying treatment strategies to address the unmet clinical needs associated with AATD.
• In addition, supportive government initiatives for rare diseases, along with favorable regulatory frameworks such as orphan drug designations and accelerated approval pathways, are encouraging innovation and facilitating the commercialization of new therapies.
• Rising adoption of home-based infusion services and self-administration treatment models is improving patient convenience, long-term treatment adherence, and continuity of care in AATD management.
• Further, strong pipeline activity involving gene therapy, RNA interference (RNAi), and genome-editing technologies is expected to transform the treatment landscape by offering potentially curative alternatives to lifelong augmentation therapy.
• Expansion of plasma collection infrastructure and fractionation capabilities by major manufacturers is strengthening supply chain stability and ensuring sustained availability of alpha-1 proteinase inhibitor therapies.
• Moreover, increasing emphasis on multidisciplinary disease management programs, patient registries, and real-world evidence generation is supporting optimized treatment pathways, reimbursement decisions, and long-term clinical outcome assessment.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Analysis

Based on treatment type, the market is segmented into medication, therapy, and surgery. The medication segment is further divided into alpha-1 proteinase inhibitor, bronchodilators, corticosteroids and other medications. The medication segment dominated the market with USD 2.2 billion in 2025.

• The medication segment represents a key component of the alpha-1 antitrypsin deficiency (AATD) treatment market, focusing on symptom management, slowing disease progression, and reducing complications associated with pulmonary and hepatic manifestations of the disorder.
• AATD commonly leads to severe respiratory diseases such as emphysema and chronic obstructive pulmonary disease (COPD), thereby increasing the clinical importance of pharmacological interventions in disease management.
• The bronchodilators are widely used to improve airflow and breathing efficiency by relaxing airway muscles in patients suffering from AATD-related COPD and respiratory impairment.
• Corticosteroids also play a significant role in reducing airway inflammation, minimizing exacerbations, and preventing progressive lung tissue damage.
• In addition, antibiotics are frequently administered to manage recurrent respiratory infections, as patients with compromised lung function are highly susceptible to bacterial infections and pulmonary complications.
• Meanwhile, the therapy segment is witnessing notable growth due to increasing adoption of alpha-1 proteinase inhibitor augmentation therapy and rising preference for long-term disease-modifying treatment approaches aimed at preserving lung function and improving quality outcomes.

Based on route of administration, the alpha-1 antitrypsin deficiency disease treatment market is divided into parenteral, intranasal, and oral. The parenteral segment dominated in 2025 and is anticipated to grow at a CAGR of 8% over the forecast years.

• The parenteral route of administration remains a critical component in the treatment of alpha-1 antitrypsin deficiency disease, owing to its ability to provide rapid and efficient delivery of therapeutics directly into systemic circulation.
• In the AATD treatment landscape, augmentation therapy administered through intravenous infusion of purified human alpha-1 antitrypsin protein represents the primary parenteral treatment approach.
• The parenteral route is highly preferred because it enables achievement of optimal plasma concentrations of alpha-1 antitrypsin, thereby helping reduce progressive lung tissue damage and slowing disease progression.
• Increasing use of infusion centers and home-based intravenous administration services is further supporting segment growth by improving treatment accessibility and patient adherence.
• On the other hand, the oral segment is gaining traction due to ongoing research focused on small-molecule therapeutics and oral modulators, along with growing patient preference for convenient non-infusion treatment alternatives.

Based on age group, the alpha-1 antitrypsin deficiency disease treatment market is divided into pediatric and adult. The adult segment is projected to reach USD 5.9 billion by the end of 2035.

• The adult segment accounts for a major share of the market, primarily due to the higher prevalence of disease manifestation among adults aged between 30 and 50 years.
• AATD often remains undiagnosed until adulthood, when cumulative lung damage results in severe respiratory disorders such as chronic obstructive pulmonary disease (COPD) and emphysema.
• Growing awareness regarding genetic testing and increasing adoption of advanced diagnostic technologies are supporting earlier diagnosis and timely therapeutic intervention among adults.
• In addition, rising smoking prevalence, environmental exposure to pollutants, and lifestyle-related risk factors are further contributing to disease progression in the adult population, thereby increasing treatment demand.
• Meanwhile, the pediatric segment is expected to witness steady growth owing to increasing early-stage diagnosis of AATD in children and rising awareness regarding pediatric liver complications associated with the disorder.

Based on end use, the alpha-1 antitrypsin deficiency disease treatment market is divided into hospitals, specialty clinics and other end users. The hospitals segment is expected to hold the highest market share of 58.8% in 2025.

• The hospital segment plays a central role in the diagnosis, treatment initiation, and long-term management of alpha-1 antitrypsin deficiency disease.
• Hospitals frequently serve as the primary point of care for patients presenting with severe respiratory complications, emphysema, liver disease, and other AATD-related conditions requiring multidisciplinary clinical management.
• The complex nature of AATD necessitates coordinated care involving pulmonologists, hepatologists, respiratory therapists, and genetic counselors, which is readily available within hospital settings.
• Furthermore, hospitals are actively involved in clinical trials and therapeutic innovation, providing infrastructure for clinical trials evaluating advanced therapies such as gene therapy, stem cell therapy, and RNA-based treatment approaches.
• On the other hand, the specialty clinics segment is expanding due to the growing importance of pulmonology centers and rare disease clinics in delivering specialized diagnostic services, infusion therapy, and personalized disease management programs for patients with AATD.

North America Alpha-1 Antitrypsin Deficiency Disease Treatment Market

The North America market dominated the global market with a market share of 60.2% in 2025.

• The region maintains its leadership position due to widespread availability of advanced genetic screening technologies, high awareness regarding rare pulmonary disorders, and early adoption of intravenous alpha-1 proteinase inhibitor augmentation therapies.
• Strong presence of leading biopharmaceutical companies, established plasma collection infrastructure, and well-developed infusion therapy networks are supporting continuous treatment availability across the region.
• Increasing prevalence of chronic obstructive pulmonary disease (COPD) and emphysema associated with AATD, along with growing utilization of precision medicine approaches, is further accelerating market demand.
• Favorable reimbursement frameworks for orphan diseases, active clinical research initiatives, and strong support from patient advocacy organizations continue to strengthen long-term market growth.

The U.S. alpha-1 antitrypsin deficiency disease treatment market was valued at USD 1.4 billion and USD 1.5 billion in 2022 and 2023, respectively. The market size reached USD 1.7 billion in 2025, growing from USD 1.6 billion in 2024.

• The U.S. market is characterized by strong research and development activity focused on augmentation therapies, RNA-based therapeutics, and gene-editing technologies for alpha-1 antitrypsin deficiency treatment.
• High disease awareness, favorable rare disease policies, and increasing genetic testing rates are supporting early diagnosis and timely treatment initiation.
• The country also benefits from support provided by organizations such as the Alpha-1 Foundation, which actively funds research programs and promotes patient education and treatment accessibility.
• In addition, increasing integration of telemedicine, remote patient monitoring, and home-based infusion services is improving treatment adherence and long-term disease management outcomes.
• Ongoing clinical trials evaluating next-generation biologics and gene therapies are expected to further strengthen the U.S. market outlook over the forecast period.

Europe Alpha-1 Antitrypsin Deficiency Disease Treatment Market

Europe market accounted for USD 836.7 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Market growth is supported by strong national rare disease frameworks, expanding diagnostic coverage, and increasing adoption of augmentation therapies across major European countries.
• The presence of approved therapies such as Respreeza and Alfalastin is enhancing treatment accessibility and supporting broader disease management across the region.
• Increasing collaboration between rare disease reference centers, respiratory specialists, and patient registries is improving standardized clinical management and patient monitoring practices.
• Furthermore, rising investments in rare disease research, coupled with supportive healthcare reimbursement systems in Western Europe, are contributing to sustained market expansion.

The UK market is experiencing robust growth in Europe alpha-1 antitrypsin deficiency disease treatment market.

• The UK market benefits from the strong role of the National Health Service (NHS), which facilitates access to diagnostic services, specialist consultations, and advanced treatment options for patients with AATD.
• AATD is increasingly recognized as a major contributor to chronic obstructive pulmonary disease (COPD), emphysema, and liver-related disorders, supporting growing demand for early screening and disease management.
• The country’s well-established healthcare infrastructure and government-supported reimbursement programs continue to improve patient access to treatment and long-term monitoring services.
• In addition, organizations such as the Alpha-1 UK Support Group are playing an important role in increasing public awareness, promoting patient advocacy, and supporting educational initiatives related to rare respiratory diseases.
• The growing focus on personalized medicine and genetic testing is further expected to strengthen market growth in the UK.

Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Treatment Market

The Asia-Pacific market is witnessing substantial growth of 8.7% during the analysis period.

• The Asia Pacific region is emerging as a high-growth market due to rising healthcare expenditure, increasing awareness regarding rare genetic disorders, and continuous improvements in healthcare infrastructure.
• Countries such as Japan, China, and South Korea are witnessing increased research activity and strategic collaborations with global pharmaceutical and biotechnology companies aimed at expanding access to advanced therapies.
• Growing focus on rare disease management, increasing adoption of precision medicine, and expanding genetic testing capabilities are supporting earlier diagnosis of AATD across the region.
• In addition, rising prevalence of respiratory diseases, urban pollution exposure, and expanding healthcare insurance coverage are contributing to growing demand for disease management solutions.

China market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• Market growth in China is supported by expanding rare disease policies, increasing hospital-based genetic testing programs, and improving specialist training related to hereditary respiratory disorders.
• Rising awareness regarding chronic respiratory diseases and inherited genetic conditions is contributing to higher diagnosis rates of AATD among the population.
• The country is also witnessing increasing investment in biotechnology innovation and precision medicine initiatives, which is expected to support future development of advanced therapies.
• However, limited availability and high cost of approved augmentation therapies continue to restrict widespread treatment adoption, thereby creating significant long-term market opportunities for international and domestic manufacturers.

Latin American Alpha-1 Antitrypsin Deficiency Disease Treatment Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• The Brazil market is driven by improving recognition of rare genetic disorders, increasing availability of specialist respiratory care, and gradual expansion of augmentation therapy access in major urban healthcare centers.
• Expansion of private healthcare infrastructure, specialty hospitals, and infusion therapy centers is improving patient access to advanced treatment options.
• Increasing collaborations with international healthcare organizations and rising imports of plasma-derived therapies are supporting market development across the country.
• Furthermore, growing awareness regarding chronic respiratory diseases and increasing investments in diagnostic capabilities are expected to support earlier disease identification and long-term market growth.

Middle East and Africa Alpha-1 Antitrypsin Deficiency Disease Treatment Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.

• Market growth is supported by increasing government investments in healthcare modernization and rising focus on genetic and rare diseases under the Vision 2030 healthcare transformation program.
• The establishment of specialized respiratory disease centers and genetic disorder clinics is contributing to improved diagnosis and disease management across the country.
• Increasing healthcare expenditure, expansion of advanced hospital infrastructure, and growing awareness regarding hereditary respiratory diseases are further supporting market expansion.
• Additionally, the country’s growing reliance on imported biologics and orphan drugs is creating strong demand for long-term augmentation therapy solutions and specialized rare disease treatments.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share

The global alpha‑1 antitrypsin deficiency (AATD) disease treatment market is characterized by a highly concentrated and specialized competitive landscape, with a small group of leading companies accounting for approximately 90% of global market revenues. Grifols, CSL Behring, and Takeda Pharmaceuticals collectively dominate the market through their approved alpha‑1 proteinase inhibitor augmentation therapies, supported by long‑standing clinical adoption, established manufacturing capabilities, and strong positions in key developed markets.

These companies benefit from deep expertise in plasma‑derived biologics and rare disease management, enabling them to maintain leadership in a market where augmentation therapy remains the only approved disease‑specific pharmacological treatment for AATD. Their dominance is reinforced by integrated plasma collection networks, large‑scale fractionation facilities, and well‑established home‑infusion and specialty distribution channels, particularly across North America and Europe.

Strategic investments in plasma manufacturing capacity, lifecycle management of existing brands, and selective partnerships continue to shape the competitive environment. Grifols has strengthened its leadership through expansion of plasma infrastructure and global supply capabilities, while CSL Behring has reinforced its European and U.S. presence with RESPREEZA and ZEMAIRA. Takeda Pharmaceuticals has differentiated its position through GLASSIA, the only ready‑to‑use liquid formulation approved for self‑administration. Collectively, these players are also advancing next‑generation pipelines, including recombinant, gene‑based, and RNA‑targeted approaches, positioning the market for potential long‑term transformation beyond traditional augmentation therapy.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Companies

Prominent players operating in the alpha-1 antitrypsin deficiency disease treatment industry are as mentioned below:

• Manufacturers
  • CSL Behring
  • Grifols
  • Takeda Pharmaceutical
  • Kamada
  • LFB Biotechnologies
• Pipeline/emerging players
  • Prime Medicine
  • Jaguar Gene Therapy
  • Intellia Therapeutics
  • Inhibrx
  • Arrowhead Pharmaceuticals
  • Octapharma
• Service providers     
  • The Johns Hopkins Hospital
  • The General Hospital
  • National Jewish Health

• Grifols

Grifols holds the leading position in the global alpha‑1 antitrypsin deficiency disease treatment market, supported by its flagship PROLASTIN / PROLASTIN‑C augmentation therapies and the world’s largest vertically integrated plasma donation and manufacturing network. The company’s strong market presence is reinforced by long‑term patient reliance on augmentation therapy, extensive global distribution, and continuous investments in plasma collection infrastructure, strengthening supply stability and long‑term market leadership.

• CSL Behring

CSL Behring maintains a strong competitive standing in the AATD treatment landscape through ZEMAIRA in the U.S. and RESPREEZA across Europe, backed by deep expertise in rare diseases and plasma‑derived biologics. The company continues to reinforce its position through investments in manufacturing capacity, lifecycle management of approved products, and expansion of access to augmentation therapy across key developed markets.

• Takeda Pharmaceuticals

Takeda Pharmaceuticals plays an important role in the global AATD market through GLASSIA, the only ready‑to‑use liquid alpha‑1 proteinase inhibitor approved for self‑administration. The company’s competitive position is supported by strong adoption in home‑infusion settings, well‑established specialty distribution channels, and integration of AATD treatment within Takeda’s broader rare disease portfolio, supporting sustained growth and patient reach.

Alpha-1 Antitrypsin Deficiency Disease Treatment Industry News

• In July 2024, GSK announced the ongoing clinical development of GSK-5462688, an investigational treatment for alpha-1 antitrypsin deficiency, which is currently in Phase II clinical trials. GSK-5462688 is designed to address the genetic disorder alpha-1 antitrypsin deficiency, which can lead to severe lung and liver disease. The outcome of this trial is anticipated to significantly impact GSK's position in the treatment landscape for genetic disorders.

• In July 2024, Intellia Therapeutics received authorization to initiate a Phase 1/2 clinical trial for NTLA-3001, a groundbreaking gene editing treatment targeting alpha-1 antitrypsin deficiency. NTLA-3001 represents Intellia’s first wholly owned CRISPR-based in vivo targeted gene insertion candidate to progress into clinical trials. This strategy is expected to add value to the company’s business portfolio.
• In January 2024, Sanofi agreed to acquire Inhibrx following the spin‑off of non‑INBRX‑101 assets into a new publicly traded entity, with consideration including cash, CVRs, and equity in New Inhibrx. The acquisition included INBRX‑101, a recombinant protein candidate for alpha‑1 antitrypsin deficiency, designed to achieve serum AAT normalization with less frequent dosing compared to existing augmentation therapies.

The alpha-1 antitrypsin deficiency disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Alpha-1 proteinase inhibitor
  • Bronchodilators
  • Corticosteroids
  • Other medications
• Therapy
  • Augmentation therapy
  • Oxygen therapy
  • Other therapies
• Surgery

Market, By Route of Administration

• Parenteral
• Intranasal
• Oral

Market, By Age Group

• Pediatric
• Adult

Market, By End Use

• Hospitals
• Specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE